Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Cushing Syndrome 4ACTH Syndrome, Ectopic 4Pituitary Diseases 3Pituitary ACTH Hypersecretion 3Hirsutism 2Choristoma 2Adrenal Cortex Neoplasms 2Triple Negative Breast Neoplasms 1Prostatic Neoplasms 1Ovarian Neoplasms 1Neoplasms 1Leiomyoma 1Fallopian Tube Neoplasms 1Carcinoma, Ovarian Epithelial 1Breast Neoplasms 1

Interventions

Prednisone 112Docetaxel 87Leuprolide 79enzalutamide 72Abiraterone Acetate 67bicalutamide 53Goserelin 50acetyl-2-naphthylalanyl-3-chlorophenylalanyl-1-oxohexadecyl-seryl-4-aminophenylalanyl(hydroorotyl)-4-aminophenylalanyl(carbamoyl)-leucyl-ILys-prolyl-alaninamide 42Radiotherapy 39abiraterone 28Magnetic Resonance Spectroscopy 27Gonadotropin-Releasing Hormone 24gallium 68 PSMA-11 23apalutamide 22Androgen Antagonists 22luprolide acetate gel depot 21sipuleucel-T 20Radiosurgery 20Triptorelin Pamoate 18cabazitaxel 17cabozantinib 16Radiotherapy, Intensity-Modulated 16Flutamide 16pembrolizumab 15radium Ra 223 dichloride 14Prednisolone 14Nivolumab 14Dutasteride 14Dexamethasone 14Radiation 13

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Has results × Prostatic Neoplasms × Mifepristone × Clear all
NCT02012296 2022-07-13

Enzalutamide and Mifepristone in Treating Patients With Metastatic Hormone Resistant Prostate Cancer

University of Chicago

Phase 1/2 Completed
88 enrolled 14 charts
Genitourinary

Prostatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡